OVID THERAPEUTICS INC (OVID) Stock News

NASDAQ:OVID - Nasdaq - US6904691010 - Common Stock - Currency: USD

0.5261 +0.05 (+9.6%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

OVID Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Benzinga - Mentions: CDNA CLSD WINT HYPR ...

12 Health Care Stocks Moving In Thursday's Intraday Session

21 days ago - By: Benzinga - Mentions: VNRX OGEN XCUR VERO ...

12 Health Care Stocks Moving In Friday's After-Market Session

23 days ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

23 days ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

2 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

a month ago - By: Yahoo Finance - Mentions: TSLA NUVB

Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?

a month ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

a month ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

2 months ago - By: Zacks Investment Research - Mentions: CVAC

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

2 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

2 months ago - By: Zacks Investment Research - Mentions: FTRE

Fortrea Holdings Inc. (FTRE) Q1 Earnings and Revenues Beat Estimates

2 months ago - By: Zacks Investment Research - Mentions: ANIP

ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates

2 months ago - By: Zacks Investment Research - Mentions: JAZZ

Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates

2 months ago - By: Zacks Investment Research - Mentions: IBRX

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

4 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

4 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

4 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

5 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

5 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

5 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

5 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

5 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

5 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

8 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting

8 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results

8 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results

9 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics to Host Investor Event

10 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin

10 months ago - By: Ovid Therapeutics Inc.

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

10 months ago - By: Ovid Therapeutics Inc.

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

11 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at Upcoming September Investor Conferences

11 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at Upcoming September Investor Conferences